A 62-year-old woman from Delhi presents with a 3-year history of progressive pain and stiffness in both knees, worse in the morning and after prolonged sitting. She has a BMI of 28 kg/m². On examination, there is crepitus on knee flexion, mild effusion, and bony enlargement of the joint margins. X-ray of both knees shows joint space narrowing, osteophytes, and subchondral sclerosis. She has tried NSAIDs with partial relief. Which of the following is the most appropriate next step in management?

Explanation

## Management of Symptomatic Knee Osteoarthritis ### Clinical Context This patient has established primary osteoarthritis (OA) of the knee with radiological confirmation (Kellgren-Lawrence Grade 3–4 features: joint space narrowing, osteophytes, sclerosis). She has failed conservative management with NSAIDs and requires escalation. ### Why Intra-Articular Corticosteroid Injection? **Key Point:** Intra-articular corticosteroid injection is the standard next step for symptomatic OA when oral NSAIDs provide inadequate relief and before considering surgical intervention. **High-Yield:** Corticosteroid injections (triamcinolone acetonide 40 mg or methylprednisolone 40 mg) are guideline-recommended for: - Moderate-to-severe symptomatic OA with functional impairment - Effusion present (improves drug delivery and reduces inflammation) - Bridge therapy while optimizing weight management and physiotherapy - Repeat injections every 3–4 months (maximum 3–4 per year per joint) **Clinical Pearl:** The presence of effusion on examination is a favorable prognostic indicator for corticosteroid injection efficacy. The anti-inflammatory effect reduces synovitis and provides pain relief lasting 6–12 weeks in 70–80% of patients. ### Comparison of Options | Intervention | Indication | Evidence | Timing | |---|---|---|---| | **Intra-articular corticosteroid** | Symptomatic OA, failed NSAIDs, effusion | Strong (EULAR, ACR) | Next step | | Hyaluronic acid | Mild-to-moderate OA, NSAID intolerance | Moderate (variable efficacy) | Alternative if CI to steroids | | Glucosamine | Mild OA, symptom modification | Weak (GAIT trial negative) | Adjunct only | | Total knee arthroplasty | Severe OA, failed conservative therapy, poor QoL | Gold standard | Last resort (after 6–12 months of medical management) | **Mnemonic:** **CIAO** — **C**orticosteroid (first-line injection), **I**ntra-articular, **A**fter NSAIDs fail, **O**ther options later. ### Why Not the Others? - **Hyaluronic acid:** Second-line for patients with NSAID intolerance or contraindications; evidence is weaker than corticosteroids. - **Glucosamine:** GAIT trial (2006) and subsequent meta-analyses show no significant benefit over placebo for pain or joint space narrowing; not recommended as monotherapy. - **Total knee arthroplasty:** Premature at this stage. TKA is reserved for severe OA with failed conservative management (6–12 months) and significant functional impairment affecting quality of life. This patient has not exhausted injectable options.